By Dr. Gabriela Lenarczyk Dr. Lenarczyk is a 2024-2025 Edison Fellow. This blog post is in partial fulfillment of obligations for the Thomas Edison Innovation Law and Policy Fellowship. Recently resurfaced […]
IPPI Cautions that Pharmaceutical Tariffs Would Harm Patients and U.S. Innovation Leadership
IPPI has submitted formal comments to the U.S. Department of Commerce regarding its Section 232 investigation of pharmaceutical imports, cautioning against imposing tariffs on medicines and their ingredients. In our […]
[Archived Post] What the FTC Gets Wrong About the FDA’s Orange Book
By Emily Michiko Morris & Douglas Park The high cost of some pharmaceuticals is a complex issue, but the Federal Trade Commission’s (FTC’s) most recent criticism of pharmaceutical patents’ role […]
[Archived Post] Professors Erika Lietzan and Kristina Acri Argue That Current Data Do Not Support Evergreening Allegations
By Jack Ring In their forthcoming paper, Solutions Still Searching for a Problem: A Call for Relevant Data to Support “Evergreening” Allegations,[1] C-IP2 Senior Scholars Erika Lietzan of Mizzou Law […]
[Archived Post] A View from Both Sides: COVID-19, the TRIPS Waiver, IP Rights, and How to Increase the Supply of Vaccines
Issue The United States and other wealthy nations have access to plenty of COVID-19 vaccine doses and thus are beginning to get the pandemic under control, while less affluent countries […]
[Archived Post] WTO IP Waiver Too Simplistic: Global Vaccine Tech-Transfer Needs Other Strategies
By Yogesh Pai Since October 2020, India and South Africa, joined by two-thirds of the WTO Members (African Group, LDCs and most of developing world) have been actively pursuing other […]
[Archived Post] The Tradeoffs Involved in New Drug Approval, Expanded Access, and Right to Try
The following post comes from CPIP Senior Fellow for Life Sciences Erika Lietzan, and it is cross-posted here from the Objective Intent blog with permission. This note explains some of […]
[Archived Post] CPIP Scholars Join Comments to FTC on How Antitrust Overreach is Threatening Healthcare Innovation
On December 21, 2018, CPIP Senior Scholars Adam Mossoff and Kristen Osenga joined former Federal Circuit Chief Judge Randall Rader and SIU Law’s Mark Schultz in comments submitted to the […]